A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...
Zacks Investment Research on MSN3d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...
Shares of DexCom Inc. slipped 3.69% to $69.47 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.33% to 5,693.31 and Dow Jones ...
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
DexCom (NasdaqGS:DXCM) witnessed a 4% increase in its share price over the past week, as the company announced a significant integration of its G7 Continuous Glucose Monitoring Systems with Nanowear's ...
DexCom Inc. closed 46.96% short of its 52-week high of $142.00, which the company achieved on March 26th.
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...
DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback